Literature DB >> 19581813

Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study.

Maurizio Biselli1, Annagiulia Gramenzi, Massimo Del Gaudio, Matteo Ravaioli, Giovanni Vitale, Stefano Gitto, Gian Luca Grazi, Antonio Daniele Pinna, Pietro Andreone, Mauro Bernardi.   

Abstract

BACKGROUND: Alcoholic liver cirrhosis (ALC) is a leading indication for orthotopic liver transplantation (OLT). GOALS: To investigate the long-term outcome of OLT for ALC compared with patients transplanted for hepatitis C virus (HCV) infection. STUDY: From 1987 to 2001, 49 OLT were performed for ALC and 173 for HCV. From these contemporary groups we matched 1:2 ALC patients (cases) to 98 HCV (controls). The following variables were analyzed: survival, retransplantation, rejection, primary nonfunction, infections, de novo tumors, cardiovascular and neurologic complications, and alcoholic recurrence.
RESULTS: Actuarial survival rate at 9 years was comparable for cases and controls. Actuarial graft survival rate at 9 years was significantly higher in cases (78% vs. 60%; P=0.026). The retransplantation rate was higher in controls (21% vs. 4%; P=0.007). Post-OLT complications were not significantly different. The alcoholic recidivism rate was 28% without influence on patients or graft survival, whereas relapse of HCV caused the majority of death in controls (30%; P=0.042). At multivariate analysis retransplantation was the only predictor of patient survival (odds ratio: 4.35; 95% confidence interval: 2.16-8.74; P<0.001), whereas HCV was associated with a 2-fold probability of graft failure (odds ratio: 1.97; 95% confidence interval: 1.02-3.81; P=0.032).
CONCLUSIONS: The long-term outcome of OLT for ALC is comparable to that for HCV, even if graft survival is significantly better among ALC. These data support ALC as an excellent indication for OLT.

Entities:  

Mesh:

Year:  2010        PMID: 19581813     DOI: 10.1097/MCG.0b013e3181a390a8

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

1.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

Review 2.  Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis.

Authors:  Carlos Jiménez-Romero; Iago Justo-Alonso; Félix Cambra-Molero; Jorge Calvo-Pulido; Álvaro García-Sesma; Manuel Abradelo-Usera; Oscar Caso-Maestro; Alejandro Manrique-Municio
Journal:  World J Hepatol       Date:  2015-05-08

Review 3.  Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?

Authors:  Marco Dall'Agata; Annagiulia Gramenzi; Maurizio Biselli; Mauro Bernardi
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

4.  KASL clinical practice guidelines: management of alcoholic liver disease.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2013-09-30

5.  Assessment of nutritional status and health-related quality of life before and after liver transplantation.

Authors:  María Teresa García-Rodríguez; María Del Carmen Piñón-Villar; Beatriz López-Calviño; Alejandra Otero-Ferreiro; Francisco Suárez-López; Manuel Gómez-Gutiérrez; Salvador Pita-Fernández
Journal:  BMC Gastroenterol       Date:  2015-01-22       Impact factor: 3.067

Review 6.  Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease.

Authors:  Stefano Gitto; Lucia Golfieri; Fabio Caputo; Silvana Grandi; Pietro Andreone
Journal:  Biomolecules       Date:  2016-01-15

7.  Alcohol relapse and its predictors after liver transplantation for alcoholic liver disease: a systematic review and meta-analysis.

Authors:  Lancharat Chuncharunee; Noriyo Yamashiki; Ammarin Thakkinstian; Abhasnee Sobhonslidsuk
Journal:  BMC Gastroenterol       Date:  2019-08-22       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.